Jefferson Capital Inc (JCAP)

That is what data from large, well-designed and executed phase 3 trials will finally answer. We’ll likely know one way or the other by sometime in 2030. That, of course, assumes Anavex will still around.

NEW UPDATE ON VUME 1.3.34. Njew versions every day! Looking better and betterr and more complete

NVDA! a interest rate fear hits big tech stocks
https://investorshub.advfn.com/uimage/uploads/2026/6/6/wfbnbIMG_2174.png

Wertheim & CO delivers high-quality advisory solutions tailored to premier privately held middle-market businesses and private investment firms.


Discreet and confidential transactions handled through private negotiations.



Full-spectrum M&A ad

🙏🙏🙏

WHAT'S YOUR SOURCE

Five year subchapter 5 plan for Nutranomics INC. - 2026 is our year.

https://www.troutman.com/wp-content/uploads/2025/03/tp_creditors-rights-toolkit_subchaptervbankruptcy.pdf

Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®June 6, 2026 4:45 PM
Business Wire New data from CATALYST and MOMENTUM trials presented

Nasrat would not have delayed if he was not sure we can do it and get paragraph 4 first to file.

He delivers.

Here ya go...

Memorandum:

https://drive.google.com/file/d/1ur0tbW0KGZv4LJm4p2GHG5uJGQQqOnTN/view?usp=sharing

Declaration:

https://drive.google.com/file/d/1LoHKsClX1RIQn3ymAbx_qr1mNUwMVPSc/view

I haven't read them yet. Up Nor

This one has been a total POS. I finally dumped it awhile ago before that 1 for 2500 reverse split. Of course they will dilute again. Will never be anything and was just a stinky OTC trip pinky that burned all previous shareholders.

I'd be stunned if there were an acquisition announcement this year and I certainly don't oppose a buyout at some point in the distant future. Part of my concern is my cost basis and selling price, as I'm not one of the fortunate investors who owns this at a sub-$1 value. If an acquisition happens

“ABT is now beset by (spurious, IMO) litigation on multiple fronts in its nutrition business”
Gives me pause too but a pretty close to worst case scenario may be priced in already but I can’t really be sure. Bayer is the poster child for the worst case scenario and they may be getting good ne

If you don't think MMs manipulate OTC prices I can see why you think Nexboard is real. That's why they are called Market MAKERS. Do you think this run of 350% wasn't due to the note holders and the MM manipulating the price. Just like any of the groups that follow their leader they run the volume an

My3sons,, it's not the first time they're posting negative articles. As you said, it's more a matter of pattern of analysis that biased the result. 

I've left little doubt that my position in NWBO is concentrated, it became more so with AVXL's failure to get European approval, nearly all my position there has been eliminated. If I'm right my kids will be set for life, if not we'll still be sitting on a couple million in real estate equity.

$BIEI $BYND Put on radar!!

They are obviously focusing on certification. That will address every issue, including revenue, PPS, and getting back on the QB.

I go long term on a lot of shares over the next few weeks. Then a bunch more in December. It feels good to cross over to the lower tax bracket. I see very little risk of being bought out in 2026. 

TAT .... THAT WOULD BE A GREAT IDEA . WITH PINKY ANYTHING IS POSSIBLE

Disagree as usual, and no one's shorting OTC unless they have $2.50 a share margin requirement, duh!

$.0089 Hey, waggy, please pick up milk while you're out, and some prunes! Some have said I'm full of it! 🤣

Many times when developments are stung out/delayed, or take longer than expected, they are BIG DEVELOPMENTS! This is the case now; been rumors of something for a fe

Sorry wrong board
Snup

Snup? Why so serious? Downcast?
Elite whoppers
Letter to the shareholders
Sequest approval just a labelling formality now
Mikah is mothballed
We will go to NASDAQ and trade over a dollar soon.
Stock was approximately trading where it was 10 years ago and eli